US2005158769A1PendingUtilityA1

Method for cloning and producing the MseI restriction endonuclease

Assignee: NEW ENGLAND BIOLABS INCPriority: Oct 12, 2000Filed: Dec 21, 2004Published: Jul 21, 2005
Est. expiryOct 12, 2020(expired)· nominal 20-yr term from priority
C12N 9/1007C12N 9/22
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for cloning restriction-modification system is provided whereby the target modification methylase is produced and confers full protection during all growth phases in which the cognate restriction enzyme is present. The method is employed in the cloning of the MseI restriction-modification system.

Claims

exact text as granted — not AI-modified
1 . A method for producing a target restriction endonuclease, which method comprises: 
 (a) isolating a gene coding for a protective modification methyltransferase;    (b) obtaining an expression construct for the modification methyltransferase gene that allows complete protection of the host microorganism at substantially all growth phases, without leading to toxicity;    (c) isolating a gene for the cognate restriction endonuclease;    (d) placing the restriction endonuclease gene of step (c) into an expression vector; and    (e) combining the vector of step (d) with the vector of step (b) in a suitable host such that the combined vectors can be stably and reproducibly reisolated from storage in an expression-competent form.    
     
     
         2 . The method of  claim 1 , wherein the growth phases examined of step (b) are selected from one or more of the group consisting of the logarithmic phase, stationary phase, a resting state achieved by starvation for carbon or nitrogen or other essential nutrient, a phase in which cells are in a special physiological state or in a phase in the presence of physiological insults.  
     
     
         3 . The method of  claim 1 , in which step (b) comprises identifying regulatory elements capable of driving expression of the methyltransferase gene during said growth phases and placing these elements at an appropriate location in the expression construct.  
     
     
         4 . The method of  claim 3 , in which selection is imposed by digesting pooled preparations of the vector with the target restriction endonuclease.  
     
     
         5 . The method of  claim 1 , in which the expression vector is selected from pUC19, pBluescript, PGEM, pRRS, pBR322 or from among moderate copy vectors selected from pACYC4, pSC101, or equivalents or from among unit copy vectors selected from F or pBELOBac11 or P1 or P1 or equivalents or from among vectors expressing target proteins from foreign promoters such as the T7 promoter selected from pET3a, pET21d or similar plasmids or vectors designed to provide very low basal expressions.  
     
     
         6 . The method of  claim 5 , in which the expression vector comprises a vector with low basal expression.  
     
     
         7 . The method of  claim 6 , in which the expression vector includes a T7 RNA polymerase promoter.  
     
     
         8 . The method of  claim 7 , in which the expression vector includes a lambda CI regulatory sequence in the opposite sense to the expression promoter.  
     
     
         9 . The method of  claim 8 , in which the expression vector is pVR24.

Join the waitlist — get patent alerts

Track US2005158769A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.